<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Li Y</submitter><funding>Jiangxi Provincial Natural Science Foundation</funding><pagination>102783</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12856442</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>37</volume><pubmed_abstract>Spinal cord injury (SCI) is a devastating neurological disorder with substantial economic and psychological burdens, underscoring the urgent need for effective therapeutic strategies. Here, we developed a dual-responsive hydrogel composed of polydopamine (PDA) and heparin-poloxamer (HP) that enables controllable mild photothermal stimulation under near-infrared (NIR) irradiation. The PDA-HP hydrogel exhibited excellent biocompatibility, biodegradability, and stable photothermal conversion. In a mouse SCI model, in situ administration of PDA-HP combined with NIR irradiation markedly improved locomotor recovery and mitigated tissue damage. Mechanistically, PDA-HP/NIR therapy reduced oxidative stress, preserved mitochondrial structure, restored ATP production, and-most notably-normalized the maladaptive overexpression of heat-shock protein 70 (HSP70) induced by SCI, thereby decreasing apoptosis and promoting neuronal survival. Quantitative proteomics further identified stress-chaperone and mitochondrial pathways as major targets of this intervention. To our knowledge, this is the first study demonstrating that PDA-HP-mediated mild photothermal modulation restores mitochondrial function through HSP70 normalization in SCI. These findings highlight a mitochondria-targeted mild photothermal strategy as a promising and clinically translatable approach for spinal cord repair.</pubmed_abstract><journal>Materials today. Bio</journal><pubmed_title>Dual-responsive PDA-HP hydrogel enables mitochondria-targeted mild photothermal therapy for spinal cord repair.</pubmed_title><pmcid>PMC12856442</pmcid><funding_grant_id>20224BAB216047</funding_grant_id><pubmed_authors>Ran B</pubmed_authors><pubmed_authors>Zhong N</pubmed_authors><pubmed_authors>Liu X</pubmed_authors><pubmed_authors>Li Y</pubmed_authors><pubmed_authors>Zhong Q</pubmed_authors><pubmed_authors>Li J</pubmed_authors><pubmed_authors>Hu J</pubmed_authors><pubmed_authors>Fu X</pubmed_authors><pubmed_authors>Zhong H</pubmed_authors><pubmed_authors>Zhong Y</pubmed_authors><pubmed_authors>Wu G</pubmed_authors></additional><is_claimable>false</is_claimable><name>Dual-responsive PDA-HP hydrogel enables mitochondria-targeted mild photothermal therapy for spinal cord repair.</name><description>Spinal cord injury (SCI) is a devastating neurological disorder with substantial economic and psychological burdens, underscoring the urgent need for effective therapeutic strategies. Here, we developed a dual-responsive hydrogel composed of polydopamine (PDA) and heparin-poloxamer (HP) that enables controllable mild photothermal stimulation under near-infrared (NIR) irradiation. The PDA-HP hydrogel exhibited excellent biocompatibility, biodegradability, and stable photothermal conversion. In a mouse SCI model, in situ administration of PDA-HP combined with NIR irradiation markedly improved locomotor recovery and mitigated tissue damage. Mechanistically, PDA-HP/NIR therapy reduced oxidative stress, preserved mitochondrial structure, restored ATP production, and-most notably-normalized the maladaptive overexpression of heat-shock protein 70 (HSP70) induced by SCI, thereby decreasing apoptosis and promoting neuronal survival. Quantitative proteomics further identified stress-chaperone and mitochondrial pathways as major targets of this intervention. To our knowledge, this is the first study demonstrating that PDA-HP-mediated mild photothermal modulation restores mitochondrial function through HSP70 normalization in SCI. These findings highlight a mitochondria-targeted mild photothermal strategy as a promising and clinically translatable approach for spinal cord repair.</description><dates><release>2026-01-01T00:00:00Z</release><publication>2026 Apr</publication><modification>2026-06-19T04:47:16.716Z</modification><creation>2026-06-19T03:07:26.232Z</creation></dates><accession>S-EPMC12856442</accession><cross_references><pubmed>41624525</pubmed><doi>10.1016/j.mtbio.2026.102783</doi></cross_references></HashMap>